Who are Triple FF/UMEC/VI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FF/UMEC/VI, BGF MDI (PT010), GFF MDI, FF/UMEC/VI (100/62.5/25) mcg, CHF 5993 200/6/12.5 µg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/triple-ff-umec-vi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Triple FF/UMEC/VI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Triple FF/UMEC/VI (Triple FF/UMEC/VI) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ICS/LAMA/LABA combination. Area: Respiratory/Pulmonology.

phase 3 ICS/LAMA/LABA combination Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Triple FF/UMEC/VI (Triple FF/UMEC/VI) — GlaxoSmithKline. Triple FF/UMEC/VI is a combination inhaler containing a long-acting beta-2 agonist (fluticasone furoate), a long-acting muscarinic antagonist (umeclidinium), and a long-acting beta-2 agonist (vilanterol) that work together to relax airway smooth muscle and reduce inflammation in chronic obstructive pulmonary disease.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Triple FF/UMEC/VI TARGET	Triple FF/UMEC/VI	GlaxoSmithKline	phase 3	ICS/LAMA/LABA combination	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
FF/UMEC/VI	FF/UMEC/VI	Dr. Grace Parraga	marketed	Triple combination inhaler (ICS/LAMA/LABA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
BGF MDI (PT010)	BGF MDI (PT010)	Pearl Therapeutics, Inc.	phase 3	Triple-combination inhaler (ICS/LABA/LAMA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
GFF MDI	GFF MDI	Pearl Therapeutics, Inc.	phase 3	Combination inhaled corticosteroid / long-acting beta-2 agonist / long-acting muscarinic antagonist	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
FF/UMEC/VI (100/62.5/25) mcg	FF/UMEC/VI (100/62.5/25) mcg	GlaxoSmithKline	phase 3	Triple combination inhaler (ICS/LAMA/LABA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
CHF 5993 200/6/12.5 µg	CHF 5993 200/6/12.5 µg	Chiesi Farmaceutici S.p.A.	phase 3	Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ICS/LAMA/LABA combination class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Triple FF/UMEC/VI — Competitive Intelligence Brief. https://druglandscape.com/ci/triple-ff-umec-vi. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing